Drug Trial Radar · NCT03914625
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
6,720
Planned (sponsor's estimate)
Start
Jul 3, 2019
Primary completion
Sep 30, 2027
Study completion Sep 30, 2027
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Apr 16, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 365 days, up to 31 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III trial studies how well blinatumomab works in combination with chemotherapy in treating patients with newly diagnosed, standard risk B-lymphoblastic leukemia or B-lymphoblastic lymphoma with or without Down syndrome. Monoclonal antibodies, such as blinatumomab, may induce changes in the body's immune system and may interfere with the ability of cancer cells to grow and spread. Chemotherapy drugs, such as vincristine, dexamethasone, prednisone, prednisolone, pegaspargase, methotrexate, cytarabine, mercaptopurine, doxorubicin, cyclophosphamide, and thioguanine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Leucovorin decreases the toxic effects of methotrexate. Giving monoclonal antibody therapy with chemotherapy may kill more cancer cells. Giving blinatumomab and combination chemotherapy may work better than combination chemotherapy alone in treating patients with B-ALL. This trial also assigns patients into different chemotherapy treatment regimens based on risk (the chance of cancer returning after treatment). Treating patients with chemotherapy based on risk may help doctors decide which patients can best benefit from which chemotherapy treatment regimens.
Conditions
- B Acute Lymphoblastic Leukemia
- B Lymphoblastic Lymphoma
- Down Syndrome
Interventions
Asparaginase Erwinia chrysanthemiDrug
Given IV or IM
BlinatumomabBiological
Given IV
CyclophosphamideDrug
Given IV
CytarabineDrug
Given IT or IV
DexamethasoneDrug
Given PO or IV
Doxorubicin HydrochlorideDrug
Given IV
Leucovorin CalciumDrug
Given PO or IV
MercaptopurineDrug
Given PO
Mercaptopurine Oral SuspensionDrug
Given PO
MethotrexateDrug
Given IT or IV
PegaspargaseDrug
Given IV or IM
PrednisoloneDrug
Given PO or IV
PrednisoneDrug
Given PO or IV
Radiation TherapyRadiation
Undergo cranial radiation therapy
Radiation TherapyRadiation
Undergo testicular radiation therapy
ThioguanineDrug
Given PO
Vincristine SulfateDrug
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease free survival (DFS) in randomization eligible patients with higher risk features (SR-High) or standard risk average (SR-Avg) B-ALL patients based on randomization with addition of blinatumomabTime frame: 5.3 years
- DFS in boys in the SR-favorable subset of SR B-ALL with or without Down syndrome (DS)Time frame: 5.1 years
Locations
228 sites in 5 countries. Site status is shown where the registry gives one.
Children's Hospital of Alabama
Birmingham, Alabama
USA Health Strada Patient Care Center
Mobile, Alabama
Providence Alaska Medical Center
Anchorage, Alaska
Banner Children's at Desert
Mesa, Arizona
Phoenix Childrens Hospital
Phoenix, Arizona
Banner University Medical Center - Tucson
Tucson, Arizona
Arkansas Children's Hospital
Little Rock, Arkansas
Kaiser Permanente Downey Medical Center
Downey, California
City of Hope Comprehensive Cancer Center
Duarte, California
Loma Linda University Medical Center
Loma Linda, California
Miller Children's and Women's Hospital Long Beach
Long Beach, California
Children's Hospital Los Angeles
Los Angeles, California
Cedars-Sinai Medical Center
Los Angeles, California
Mattel Children's Hospital UCLA
Los Angeles, California
Valley Children's Hospital
Madera, California
UCSF Benioff Children's Hospital Oakland
Oakland, California
Kaiser Permanente-Oakland
Oakland, California
Children's Hospital of Orange County
Orange, California
Lucile Packard Children's Hospital Stanford University
Palo Alto, California
Sutter Medical Center Sacramento
Sacramento, California
University of California Davis Comprehensive Cancer Center
Sacramento, California
Rady Children's Hospital - San Diego
San Diego, California
Naval Medical Center -San Diego
San Diego, California
UCSF Medical Center-Mission Bay
San Francisco, California
Santa Barbara Cottage Hospital
Santa Barbara, California
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Torrance, California
Children's Hospital Colorado
Aurora, Colorado
Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
Denver, Colorado
Connecticut Children's Medical Center
Hartford, Connecticut
Yale University
New Haven, Connecticut
Alfred I duPont Hospital for Children
Wilmington, Delaware
MedStar Georgetown University Hospital
Washington D.C., District of Columbia
Children's National Medical Center
Washington D.C., District of Columbia
Broward Health Medical Center
Fort Lauderdale, Florida
Golisano Children's Hospital of Southwest Florida
Fort Myers, Florida
UF Health Cancer Institute - Gainesville
Gainesville, Florida
Memorial Regional Hospital/Joe DiMaggio Children's Hospital
Hollywood, Florida
Nemours Children's Clinic-Jacksonville
Jacksonville, Florida
Palms West Radiation Therapy
Loxahatchee Groves, Florida
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida
Showing 40 of 228 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.